BM
Biomea Fusion, Inc.
BMEA · NASDAQ
$1.71 -0.29% (-$0.01)
1M +7.55%
Market Cap $123.6M
P/E Ratio -
Div. Yield -
ROE 171.19%
Bulios Fair Price
$0.91
46.8% downside
Current Price
$1.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMEA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
0 /100
Expensive P/B 10.19x
PEG N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 35.19%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 88.24%
ROIC 212.95%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 3.47x
Debt/Equity 0.07x
Debt/Assets N/A
Stability
35 /100
Moderate Profitable years 0
Beta -0.30x
EPS volatility 50.15%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMEA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael J. Hitchcock
Employees
37
Headquarters
San Carlos
Upcoming events
03 NOV
Earnings
Upcoming earnings report